Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

Completed · Phase 3

Conditions studied: Parkinson Disease

In brief

The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa medication.

Key facts

Study ID

NCT00381472

Run by

GlaxoSmithKline

People needed

393

Starts

2003-06-01

Expected to finish

2004-12-01

Last updated by the study team

2017-03-23

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Idiopathic Parkinson's disease
• Modified Hoehn and Yahr Scale Stages II - IV
• Stable dose of L-dopa for at least 4 weeks prior to screening.
• Lack of control with L-dopa therapy.
• Women of child-bearing potential must use a clinically accepted form of birth control.

You may not qualify if…

• Significant and/or uncontrolled medical conditions (excluding Parkinson's disease) within 3 months of screening.
• Any abnormality, at screening, that is considered clinically relevant by the Investigator.
• Dementia
• Use of dopamine agonists within 4 weeks of screening visit.
• Participation in other investigational drug studies.

Where it is running

• GSK Investigational Site — Northridge, California, United States
• GSK Investigational Site — San Francisco, California, United States
• GSK Investigational Site — Englewood, Colorado, United States
• GSK Investigational Site — Boca Raton, Florida, United States
• GSK Investigational Site — Panama City, Florida, United States
• GSK Investigational Site — St. Petersburg, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Augusta, Georgia, United States
• GSK Investigational Site — Glenview, Illinois, United States
• GSK Investigational Site — Kansas City, Kansas, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Bingham Farms, Michigan, United States
• GSK Investigational Site — Southfield, Michigan, United States
• GSK Investigational Site — Traverse City, Michigan, United States
• GSK Investigational Site — Las Vegas, Nevada, United States
• GSK Investigational Site — Albany, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Charlotte, North Carolina, United States
• GSK Investigational Site — Durham, North Carolina, United States
• GSK Investigational Site — Raleigh, North Carolina, United States
• GSK Investigational Site — Toledo, Ohio, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.